These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34366266)

  • 1. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
    Kedmi M; Khaustov P; Ribakovsy E; Benjamini O; Avigdor A
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e929-e937. PubMed ID: 34366266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
    Akay OM; Ozbalak M; Pehlivan M; Yildiz B; Uzay A; Yigenoglu TN; Elverdi T; Kaynar L; Ayyildiz O; Yonal Hindilerden I; Goksoy HS; Izmir Guner S; Gunes AK; Sonmez M; Kurt Yuksel M; Civriz Bozdag S; Ozkurt ZN; Toptas T; Dogu MH; Salim O; Saydam G; Yavasoglu I; Ayli M; Ozet G; Albayrak M; Birtas Atesoglu E; Toprak SK; Yildirim R; Mehtap O; Kalayoglu Besisik S; Nalcaci M; Altuntas F; Ferhanoglu B
    Hematol Oncol; 2021 Oct; 39(4):498-505. PubMed ID: 34171130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
    Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R;
    Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
    Kort J; Chidiac A; El Sayed R; Massoud R; Nehme R; Bazarbachi A; El-Cheikh J
    Leuk Lymphoma; 2020 Jul; 61(7):1732-1735. PubMed ID: 32090673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
    Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
    Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary.
    Husi K; Szabó R; Pinczés LI; Földeák D; Dudley R; Szomor Á; Koller B; Gopcsa L; Illés Á; Miltényi Z
    Ann Hematol; 2023 Sep; 102(9):2555-2563. PubMed ID: 37428200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
    Forlenza CJ; Rosenzweig J; Mauguen A; Buhtoiarov I; Cuglievan B; Dave H; Deyell RJ; Flerlage JE; Franklin AK; Krajewski J; Leger KJ; Marks LJ; Norris RE; Pacheco M; Willen F; Yan AP; Harker-Murray PD; Giulino-Roth L
    Blood Adv; 2023 Jul; 7(13):3225-3231. PubMed ID: 36897253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF; Chen L; Nieto Y; Holmberg L; Johnston P; Mei M; Popplewell L; Armenian S; Cao T; Farol L; Sahebi F; Spielberger R; Chen R; Nademanee A; Puverel S; Nwangwu M; Lee P; Song J; Skarbnik A; Kennedy N; Peters L; Rosen ST; Kwak LW; Forman SJ; Feldman T
    Lancet Haematol; 2023 Jan; 10(1):e14-e23. PubMed ID: 36403579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
    Onishi M; Graf SA; Holmberg L; Behnia S; Shustov AR; Schiavo K; Philip M; Libby EN; Cassaday RD; Pagel JM; Roden JE; Maloney DG; Green DJ; Till BG; Press OW; Smith SD; Gopal AK
    Hematol Oncol; 2015 Dec; 33(4):187-91. PubMed ID: 25236531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
    Herrera AF; Palmer J; Martin P; Armenian S; Tsai NC; Kennedy N; Sahebi F; Cao T; Budde LE; Mei M; Siddiqi T; Popplewell L; Rosen ST; Kwak LW; Nademanee A; Forman SJ; Chen R
    Ann Oncol; 2018 Mar; 29(3):724-730. PubMed ID: 29272364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
    Gandolfi L; Pellegrini C; Casadei B; Stefoni V; Broccoli A; Tonialini L; Morigi A; Argnani L; Zinzani PL
    Oncologist; 2016 Dec; 21(12):1436-1441. PubMed ID: 27486201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
    Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
    Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    LaCasce AS; Bociek RG; Sawas A; Caimi P; Agura E; Matous J; Ansell SM; Crosswell HE; Islas-Ohlmayer M; Behler C; Cheung E; Forero-Torres A; Vose J; O'Connor OA; Josephson N; Wang Y; Advani R
    Blood; 2018 Jul; 132(1):40-48. PubMed ID: 29703778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.
    Bröckelmann PJ; Zagadailov EA; Corman SL; Chirikov V; Johnson C; Macahilig C; Seal B; Dalal MR; Illidge T
    Eur J Haematol; 2017 Dec; 99(6):553-558. PubMed ID: 28949403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience.
    Angelopoulou MK; Vassilakopoulos TP; Batsis I; Sakellari I; Gkirkas K; Pappa V; Giannoulia P; Apostolidis I; Apostolopoulos C; Roussou P; Panayiotidis P; Dimou M; Kyrtsonis MC; Palassopoulou M; Vassilopoulos G; Moschogiannis M; Kalpadakis C; Margaritis D; Spyridonidis A; Michalis E; Anargyrou K; Repousis P; Hatzimichael E; Bousiou Z; Poulakidas E; Grentzelias D; Harhalakis N; Pangalis GA; Anagnostopoulos A; Tsirigotis P
    Hematol Oncol; 2018 Feb; 36(1):174-181. PubMed ID: 28219112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.
    Graf SA; Gopal AK
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):151-7. PubMed ID: 25696848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.